Evidence map›Paper›PMID 42387054›Full record

ArticleNature materials2026

Intranasal DNA nanocarrier vaccines with surface-patterned antigens enhance efficacy against respiratory syncytial virus.

Xiaoyu Gao, Liting Chen, Qingqing Feng, Wei Lv, Peijun Xu, Zetao Yu, Xinwei Wang, Qinyi Zhang, Tianyu Shao, Yichao Lu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Xiaoyu GaoBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Liting ChenBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Qingqing FengBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Wei LvBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Peijun XuBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Zetao YuBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Xinwei WangBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Qinyi ZhangBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Tianyu ShaoBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Yichao LuBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Wenna LiBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Jiabeini ZhangBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Dingfei QianBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Xinze DuBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China.
Jiajia ZouBeijing Intell Nanomedicine, Beijing, China.
Linjie ChenBeijing Intell Nanomedicine, Beijing, China.
Guangjun NieBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China. niegj@nanoctr.cn.ORCID 0000-0001-5040-9793
Keman ChengBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China. chengkm@nanoctr.cn.ORCID 0009-0006-6646-0095
Xiao ZhaoBeijing Key Laboratory of Nanocarriers for Drug Delivery, National Center for Nanoscience and Technology of China, Beijing, China. zhaox@nanoctr.cn.ORCID 0000-0002-4504-5670

Funding

Beijing Municipal Science and Technology Commission Z231100007223011National Natural Science Foundation of China (National Science Foundation of China) 32222045 and 32171384National Natural Science Foundation of China (National Science Foundation of China) 32471450 and 82402462
6 · The paper itself

Abstract

Although injectable respiratory syncytial virus (RSV) pre-F vaccines are clinically established, effective intranasal alternatives remain elusive. Geometric and surface antigen display properties are critical for respiratory B cell activation, yet lack strategies for systematic optimization. Here we report a library of DNA nanocarriers with controlled dimensions and sizes, aiming to systemically evaluate the influence of geometric properties on intranasal retention. Taking advantage of the precise control on DNA nanocarriers and antigen functionalization, we organized the surface antigen patterns of pre-F monomers on DNA nanocarriers to maximize B cell activation. The optimized DNA nanocarrier-based vaccine elicited humoral immunity in mice comparable to that induced by the clinically approved trimeric mRNA vaccine against RSV, but with greater durability. While intramuscular mRNA vaccines failed to induce effective respiratory mucosal immunity, the intranasal DNA nanocarrier-based vaccine achieved robust local and systemic immune activation, conferring potent protection against RSV infection. This rational design of intranasal RSV vaccines may be a general strategy for testing and advancing potent intranasal vaccines for a range of infectious respiratory diseases.

Indexed as

Drug CarriersRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccines, DNAAdministration, IntranasalAnimalsFemaleMiceMice, Inbred BALB CNanovaccinesDrug CarriersNanovaccinesRespiratory Syncytial Virus VaccinesVaccines, DNA

Identifiers

PMID42387054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.